Landmarks On C-Reactive Protein As Inflammation Marker

Mini Review


Abstract views: 58 / PDF downloads: 24

Authors

  • Tania Leme da Rocha Martinez

DOI:

https://doi.org/10.58372/2835-6276.1221

Keywords:

Acute coronary syndrome, Atherosclerosis, C-reactive protein, Inflammation, Laboratory test

Abstract

C-reactive protein is a crucial biomarker for inflammation and widely used in assessing cardiovascular disease risk. Produced by the liver in response to inflammatory stimuli like infection or injury, C-reactive protein levels rise significantly during acute and chronic inflammation. High-sensitivity C-reactive protein testing detects even low-grade inflammation, providing greater accuracy in identifying cardiovascular risk. C-reactive protein relevance in cardiovascular health stems from its association with atherosclerosis, an inflammatory process that leads to plaque buildup in arteries. Elevated C-reactive protein levels are linked to higher risks of heart attacks, strokes, and heart failure. The JUPITER study demonstrated that using high-sensitivity C-reactive protein to guide statin therapy in high-risk individuals significantly reduced cardiovascular disease events and mortality. Beyond being a marker, C-reactive protein actively contributes to atherothrombosis by impairing endothelial function and promoting a pro-thrombotic environment. Genetic and environmental factors, such as smoking, diet, and seasonal variations, also influence C-reactive protein levels. Additionally, C-reactive protein is a strong predictor of adverse outcomes following acute coronary syndrome. Studies show that both high-sensitivity C-reactive protein and B-type natriuretic peptide, when measured 30 days after acute coronary syndrome, independently predict heart failure and cardiovascular death. In conclusion, C-reactive protein, particularly through high-sensitivity C-reactive protein testing, is a vital tool in evaluating inflammation and predicting cardiovascular risk. Its role in personalized medicine continues to grow, as ongoing research explores the genetic and environmental factors influencing C-reactive protein and its potential as a therapeutic target in inflammatory diseases. As research progresses, C-reactive protein remains a cornerstone in cardiovascular risk management.

References

Young I, Rifai N. High-sensitivity C-reactive protein and cardiovascular disease. Clin Chem. 2009; 55(2):201-202. doi: 10.1373/clinchem.2008.120527.

Collinson PO. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death: just another brick in the wall? Clin Chem. 2009; 55(2):203-205. doi: 10.1373/clinchem.2008.119198.

Jialal I, Verma S, Devaraj S. Inhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevance. Clin Chem. 2009; 55(2):206-208. doi: 10.1373/clinchem.2008.119206.

Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clin Chem. 2009; 55(2):209-215. doi: 10.1373/clinchem.2008.119214.

Koenig W. Is hsCRP back on board? Implications from the JUPITER Trial. Clin Chem. 2009; 55(2):216-208. doi: 10.1373/clinchem.2008.115915.

Mora S, Musunuru K, Blumenthal RS. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines. Clin Chem. 2009; 55(2):219-228. doi: 10.1373/clinchem.2008.109728.

Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem. 2009; 55(2):229-238. doi: 10.1373/clinchem.2008.108886.

Hingorani AD, Shah T, Casas JP, et al. C-reactive protein and coronary heart disease: predictive test or therapeutic target? Clin Chem. 2009; 55(2):239-255. doi: 10.1373/clinchem.2008.115923.

Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin Chem. 2009; 55(2):256-264. doi: 10.1373/clinchem.2008.117754.

Scirica BM, Cannon CP, Sabatine MS, et al. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem. 2009; 55(2):265-273. doi: 10.1373/clinchem.2008.117192.

Fujita Y, Kakino A, Nishimichi N, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem. 2009; 55(2):285-294. doi: 10.1373/clinchem.2008.119750.

Vollmer T, Piper C, Kleesiek K, et al. Lipopolysaccharide-binding protein: a new biomarker for infectious endocarditis? Clin Chem. 2009; 55(2):295-304. doi: 10.1373/clinchem.2008.106195.

Glynn RJ, MacFadyen JG, Ridker PM. Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem. 2009; 55(2):305-312. doi: 10.1373/clinchem.2008.120642.

Chiriboga DE, Ma Y, Li W, et al. Seasonal and sex variation of high-sensitivity C-reactive protein in healthy adults: a longitudinal study. Clin Chem. 2009; 55(2):313-321. doi: 10.1373/clinchem.2008.111245.

Rückerl R, Peters A, Khuseyinova N, et al. Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors. Clin Chem. 2009; 55(2):322-335. doi: 10.1373/clinchem.2008.112334.

Kimberly MM, Caudill SP, Vesper HW, et al. Standardization of high-sensitivity immunoassays for measurement of C-reactive protein; II: Two approaches for assessing commutability of a reference material. Clin Chem. 2009; 55(2):342-350. doi: 10.1373/clinchem.2008.115907.

Lee CC, You NC, Song Y, et al. Relation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women's Health Initiative Observational Cohort. Clin Chem. 2009; 55(2):351-360. doi: 10.1373/clinchem.2008.117176.

Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem. 2009; 55(2):361-364. doi: 10.1373/clinchem.2008.109207.

Biasucci LM, Liuzzo G, Della Bona R, et al. Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. Clin Chem. 2009; 55(2):365-368. doi: 10.1373/clinchem.2008.119156.

Ridker PM. Myocardial infarction in a 72-year-old woman with low LDL-C and increased hsCRP: implications for statin therapy. Clin Chem. 2009; 55(2):369-374; discussion 374-375. doi: 10.1373/clinchem.2008.115931.

Tracy RP. Simple and reproducible ELISA for C-reactive protein. Clin Chem. 2009; 55(2):376-377. doi: 10.1373/clinchem.2008.105403.

NACB LMPG Committee Members; Myers GL, Christenson RH, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009; 55(2):378-384. doi: 10.1373/clinchem.2008.115899.

Downloads

Published

2024-11-02

How to Cite

Tania Leme da Rocha Martinez. (2024). Landmarks On C-Reactive Protein As Inflammation Marker: Mini Review. American Journal of Medical and Clinical Research & Reviews, 3(11), 1–4. https://doi.org/10.58372/2835-6276.1221

Issue

Section

Articles